Kanghong Pharmaceutical announced that recently, its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and KHN921 injection was approved to conduct clinical trials to treat hypertrophic cardiomyopathy caused by MYBPC3 mutations. This product is an AAV gene therapy product independently developed by Hongji Biotech. In April 2026, it was approved by the US Drug Administration to conduct clinical trials in the US. Investors are reminded to pay attention to risks due to uncertain results and timing such as drug development.

Kanghong Pharmaceutical announced that recently, its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and KHN921 injection was approved to conduct clinical trials to treat hypertrophic cardiomyopathy caused by MYBPC3 mutations. This product is an AAV gene therapy product independently developed by Hongji Biotech. In April 2026, it was approved by the US Drug Administration to conduct clinical trials in the US. Investors are reminded to pay attention to risks due to uncertain results and timing such as drug development.